Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06525623 · ClinicalTrials.gov registry record · NA

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

A NA study of Acute Kidney Injury and Cirrhosis, Liver, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06525623: Recruiting NA study of Acute Kidney Injury and Cirrhosis, Liver, sponsored by Massachusetts General Hospital.

NCT06525623 is a NA study of Acute Kidney Injury and Cirrhosis, Liver that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06525623, a NA study of Acute Kidney Injury and Cirrhosis, Liver, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin? Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or a standard of care IV albumin recommendation.

Interventions

  • OTHER Recommendation: No Further Resuscitation
  • OTHER Recommendation: Resuscitation with Crystalloid
  • OTHER Recommendation: Resuscitation with Colloid
  • OTHER Recommendation: Standard of Care IV Albumin

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-09-12
Est. Completion 2027-05-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT06525623 shows while recruiting

NCT06525623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 4 interventions - of which Recommendation: No Further Resuscitation is the first listed.

NCT06525623 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06525623 about?

NCT06525623 is a clinical study titled "Initial Resuscitation for Acute Kidney Injury in Cirrhosis". The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use...

What is the current status of trial NCT06525623?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-09-12. Estimated completion is 2027-05-01.

What conditions does trial NCT06525623 study?

This clinical trial studies the following conditions: Acute Kidney Injury, Cirrhosis, Liver, Hepatorenal Syndrome.

What interventions are being tested in trial NCT06525623?

The interventions under investigation include: Recommendation: No Further Resuscitation (OTHER), Recommendation: Resuscitation with Crystalloid (OTHER), Recommendation: Resuscitation with Colloid (OTHER), Recommendation: Standard of Care IV Albumin (OTHER).

Who is sponsoring clinical trial NCT06525623?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06525623 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Kidney Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06525623's enrollment target sits among peer trials

50 56th of 74 higher than 17 of 74 other Acute Kidney Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06525623, the US trial registry maintained by the National Library of Medicine. NCT06525623 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.